Workflow
VCI Global Expands Platform Strategy with Smart Bridge Launch into US$16 Trillion Real-World Asset Tokenization Market
Globenewswire· 2025-09-09 20:10
文章核心观点 - VCI Global子公司Smart Bridge Technologies推出专注于现实世界资产(RWA)代币化的咨询业务 旨在抓住规模达16万亿美元的代币化市场机会 通过整合人工智能、资本市场咨询和区块链技术 增强公司跨行业平台能力 并实现收入多元化和利润率提升 [1][2][3] 业务战略扩展 - 新业务是公司跨行业平台战略的自然延伸 整合了资本市场咨询、人工智能、金融科技和网络安全能力 通过代币化服务连接传统金融与数字资产 [2][3] - 具体服务包括资产代币化咨询(涵盖房地产、大宗商品、碳信用、知识产权及私募股权)、受监管上市支持(新加坡、香港和美国市场)、跨境资本接入以及技术集成解决方案 [7] - 通过为资产密集型行业提供替代融资方案 生成经常性高利润率收入 并通过端到端生命周期支持深化客户关系 [8] 市场机会与定位 - 目标市场规模达16万亿美元 由波士顿咨询集团和ADDX预测 [1] - 通过将实体和金融资产转换为区块链验证的可交易工具 为客户提供新流动性渠道、透明度和全球投资者接入机会 [2] - 公司定位为金融市场创新前沿 特别专注于东南亚地区政府、企业和机构的数字化生态建设 [6][7] 技术能力与竞争优势 - Smart Bridge结合人工智能创新与资本市场洞察 提供端到端解决方案 专注于AI驱动的自动化、企业级IT解决方案和数字化转型服务 [4][5] - 采用专有军事级加密技术 满足数字主权、国家安全和企业韧性的最高标准 [9] - 子公司具备软件开发、系统集成和数字咨询的专业能力 并与区块链赋能的金融解决方案相结合 [4]
FG Nexus Announces $200 Million Share Repurchase Program
Globenewswire· 2025-09-09 20:09
Charlotte, NC, Sept. 09, 2025 (GLOBE NEWSWIRE) -- FG Nexus Inc. (Nasdaq: FGNX, FGNXP) (the “Company”), today announced that its Board of Directors has approved a Share repurchase program to acquire up to $200 million of the Company's outstanding common stock (the “Share Repurchase Program”). The Stock Repurchase Program, which is open-ended, allows the Company to repurchase its shares from time to time in the open market and in negotiated transactions. Any repurchases conducted pursuant to the Share Repurch ...
Biomerica Launches AI-Backed inFoods® IBS Trigger Food Navigator to Support Personalized IBS Therapy and Improve Patient Outcomes
Globenewswire· 2025-09-09 20:08
New AI-enabled digital tool empowers patients to confidently manage IBS symptoms and avoid the trigger foods identified by inFoods® IBS testingIBS affects an estimated 40 million adults in the U.S. and hundreds of millions worldwide IRVINE, Calif., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced diagnostic and therapeutic solutions, today announced the launch of its inFoods® IBS Trigger Food Navigator, a comprehensive AI-backed digital companion tool designed ...
Cellectar Biosciences to Participate at Oppenheimer 3rd Annual Targeted Radiopharmaceutical Therapies in Oncology Summit
Globenewswire· 2025-09-09 20:05
Highlighting Continued Progress with EMA Regarding a Potential Conditional Marketing Authorization Submission for Iopofosine I 131 to Treat Waldenstrom Macroglobulinemia (WM) in the EU; Decision on Track for Late 3Q25/Early 4Q25 Intention to Pursue an Accelerated Approval with the U.S. Food and Drug Administration for Iopofosine I 131 as a Treatment for WM Advancing Auger-Emitting Radiopharmaceutical Product Candidate into Phase 1b Clinical Trial for the Treatment of Triple-Negative Breast Cancer in 4Q25 FL ...
24/7 Market News: Ken Le, Not Stan Lee, to Lead Prodigy Silk’s Super Fiber Deliveries to Global Brands for Kraig Labs
Globenewswire· 2025-09-09 20:05
DENVER, Sept. 09, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and information, analyses Kraig Biocraft Laboratories (OTCQB: KBLB), the undisputed global leader in the development and commercialization of spider silk, appointment of Kenneth Le as Managing Director of Prodigy Silk Ltd, the Company’s wholly owned recombinant spider silk production subsidiary in Southeast Asia. The strategic promotion of Le comes at a pivota ...
NKGen Biotech, Inc. Announces Completion of NKMax Co., Ltd. Acquisition; Gains Full Control of Global Manufacturing and Intellectual Property Assets
Globenewswire· 2025-09-09 20:05
NKGen acquires controlling stake in NKMax, marking a pivotal moment in its transformation into a fully integrated, self-sustaining, cell therapy company with global manufacturing and IP control.Approximately $16.9 million paid to acquire 65% equity stake in recapitalized debt-free NKMax, with NKMax operations now expected to be funded through 2026.Funding provided by AlpineBrook Capital GP 1 Limited and NKGen CEO Dr. Paul Y. Song. SANTA ANA, Calif., Sept. 09, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OT ...
Cuprina Secures Exclusive Rights to Southeast Asia’s First UNIDO/GEF- Demonstrated Medical Waste Recycling Technology
Globenewswire· 2025-09-09 20:05
SINGAPORE, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical and biotechnology company dedicated to the development and commercialization of products for the management of chronic wounds and infertility, as well as cosmeceuticals for the health and beauty sector, today announced it has secured exclusive licensing rights to Southeast Asia’s first medical waste recycling technology developed under the oversight of the United Nations ...
24/7 Market News TEN Holdings Supercharges Growth with SaaS and Synergies
Globenewswire· 2025-09-09 20:05
Customer Boom and M&A on DeckDENVER, Sept. 09, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, reports that TEN Holdings (NASDAQ: XHLD), a provider of event planning, production, and broadcasting services through its operating subsidiary Ten Events, is demonstrating robust execution and accelerating growth, according to a recent update from All-Star Analyst Barry M. Sine, CFA, CMT. Sine, a two-time ...
zSpace and Paracosma Partner to Accelerate Certification Prep with Virtual Vehicle Inspection Trainer
Globenewswire· 2025-09-09 20:00
SAN JOSE, Calif., Sept. 09, 2025 (GLOBE NEWSWIRE) -- zSpace, Inc. (NASDAQ: ZSPC), a leader in immersive augmented reality (AR) solutions for education, today announced a strategic partnership with Paracosma Inc., an award-winning AR/VR solutions provider, to bring advanced vehicle systems training to classrooms and workforce development programs. Together, the companies will deliver the Heavy Machine & Vehicle Inspection Virtual Trainer, designed to prepare students for industry-recognized certifications an ...
HCW Biologics Reports Positive Results from Non-Human Primate Study for Its Proprietary Second-Generation T-Cell Engager Program
Globenewswire· 2025-09-09 20:00
HCW Biologics conducted investigative study to show safe dose levels of its lead drug candidate in non-human primates that were well tolerated at a level significantly higher than the identified efficacious dose level Program has addressed key challenges for first generation T-cell engagers related to manufacturability, preclinical safety profile, and ability to treat a wide spectrum of solid tumors Program is positioned for a potential high value corporate partnership MIRAMAR, Fla., Sept. 09, 2025 (GLOBE ...